arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Travere Therapeutics, Inc.

TVTX
$59.83 ▼ -0.45 (-0.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Travere Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.3B
Dividend Yield —
Revenue Growth 110.5% ↗
Op. Margin -12.8% ↗
ROIC -55.8% ↗
FCF / Share $0.42 ↗
Trailing P/E —
Price / Book 47.4x
FCF Yield 0.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$490.73M
↑ +110.5% —
Net Income Profit after all expenses
$-25.55M
↑ +92.1% —
Operating Margin Operating profit as % of sales
-12.8%
↑ +90.8% 13th
FCF / Share Free cash flow per share
$0.42
↑ +114.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
29
Returns ↑
27
Financial Health ↑
34
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 16 years · 64 quarters